Mouse Models of Leber Hereditary Optic Neuropathy in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Leber Hereditary Optic Neuropathy
Leber hereditary optic neuropathy is a mitochondrial optic neuropathy, in most cases caused by one of three point mutations in mitochondrial DNA affecting complex I, and transmitted maternally.
It presents as painless central vision loss, usually subacute and usually reaching the second eye after the first, more often in young adult men. Penetrance is incomplete, so carrying the mutation is not the same as developing the disease.
The cells that die are retinal ganglion cells, and in people the small-caliber fibers of the papillomacular bundle go first, which is why the field defect is central.
Leber Hereditary Optic Neuropathy in Experimental Research
A mouse has no macula and no papillomacular bundle, so that selectivity has no anatomical substrate to express itself in.
What a mouse model can supply is:
- The mitochondrial lesion
- The vulnerability of retinal ganglion cells to it
- The consequences, measured as ganglion cell and nerve fiber layer thinning and as electrophysiological change rather than as a central scotoma
Models also reach the lesion by different routes, some carrying a mitochondrial DNA change, others a nuclear gene or a chemical inhibitor of complex I, and those routes are not interchangeable when the question is about mitochondrial genetics.
Mouse Models of Leber Hereditary Optic Neuropathy
The mouse carries most of this work.
Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.
A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.
Published MICRON Research: Leber Hereditary Optic Neuropathy in Mice
This page lists 4 papers from the MICRON literature, published 2020 to 2025, that study Leber hereditary optic neuropathy in mice.
Of these publications:
- 4 studies used mice as the primary Leber hereditary optic neuropathy disease model.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published Leber hereditary optic neuropathy research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Electroretinography | 4 |
| Optical Coherence Tomography | 4 |
| Intravitreal Injection / Delivery | 2 |
| Topical Ophthalmic Drug Delivery | 2 |
| AAV-Mediated Ocular Gene Delivery | 1 |
| CRISPR-Based Ocular Gene Editing | 1 |
| Fundus Fluorescein Angiography | 1 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
Topical Ophthalmic Drug Delivery
A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.
AAV-Mediated Ocular Gene Delivery
An adeno-associated viral vector delivers genetic material to ocular cells, and a single administration can support long-lived transgene expression. That persistence is useful for gene augmentation and sustained therapeutic-protein expression; AAV can also deliver gene-silencing or genome-editing cargo, where long-lived expression of the editing machinery may be unnecessary or undesirable. Capsid and route of delivery jointly determine which cells are reached, so different delivery routes and vector designs give different distributions.
CRISPR-Based Ocular Gene Editing
Uses a programmable genome-editing system to alter DNA at an endogenous locus rather than adding a separate replacement copy. Depending on the editor and design, it can disrupt, correct or install a sequence, either therapeutically or to create an experimental model. Once a genomic sequence change is established, the edit itself cannot be withdrawn like a dose; where the edit is present from conception, the resulting phenotype also reflects its effects throughout development. Off-target sequence changes are a separate question that structural imaging does not establish.
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| Image-Guided OCT | 2 |
| Ganzfeld ERG System | 1 |
| Insight Software | 1 |
| MICRON (Unspecified) | 1 |
| MICRON III | 1 |
| MICRON IV | 1 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| C57BL/6J | 2 | |
| C57BL/6JNarl | 1 | |
| C57BL/6N | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Retinal Ganglion Cell Degeneration | 4 |
| Retinal Degeneration (General) | 1 |
| Retinal Pigment Epithelium Dysfunction | 1 |
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| Image-Guided OCT | 2 | Electroretinography (2), Optical Coherence Tomography (2), Intravitreal Injection / Delivery (1) |
| Ganzfeld ERG System | 1 | AAV-Mediated Ocular Gene Delivery (1), Electroretinography (1), Intravitreal Injection / Delivery (1) |
| Insight Software | 1 | Electroretinography (1), Intravitreal Injection / Delivery (1), Optical Coherence Tomography (1) |
| MICRON (Unspecified) | 1 | Electroretinography (1), Intravitreal Injection / Delivery (1), Optical Coherence Tomography (1) |
| MICRON III | 1 | CRISPR-Based Ocular Gene Editing (1), Electroretinography (1), Fundus Fluorescein Angiography (1) |
| MICRON IV | 1 | Electroretinography (1), Optical Coherence Tomography (1), Topical Ophthalmic Drug Delivery (1) |
The papers
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2025 | In vivo mitochondrial base editing restores genotype and visual function in a mouse model of LHON. | Nature Communications | Disease model | Ganzfeld ERG System | DOI · reSEARCH |
| 2025 | Vitamin A treatment restores vision failures arising from Leber's hereditary optic neuropathy-linked mtDNA mutation. | JCI Insight | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2023 | HLA-Homozygous iPSC-Derived Mesenchymal Stem Cells Rescue Rotenone-Induced Experimental Leber's Hereditary Optic Neuropathy-like Models In Vitro and In Vivo. | Cells | Disease model | Image-Guided OCT, Insight Software, MICRON (Unspecified) | DOI · reSEARCH |
| 2020 | PRICKLE3 linked to ATPase biogenesis manifested Leber's hereditary optic neuropathy. | The Journal of Clinical Investigation | Disease model | MICRON III | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.